Hearing aid reg revisions may be shelved due to de-regulatory political climate.
This article was originally published in The Gray Sheet
Executive SummaryIOL INVESTIGATIONAL DEVICE EXEMPTION REGS ON FAST TRACK as FDA's device rulemaking agenda tacks to the right. As part of an effort to speed publication of rules seen as easing regulatory burdens, FDA is pushing to issue a final rule revoking a special IDE rule for intraocular lenses. The effort reflects calls from Congress and outside groups for relaxation of device regulations.
You may also be interested in...
Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.
The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019.